Abstract
The purpose of this study was to determine the effectiveness and toxicity of local continuous immunotherapy of prostatic cancer. A group of 60 young male Copenhagen rats with Dunning adenocarcinoma of the prostate, implanted subcutaneously into both flanks, after proven tumor growth, were treated with either human interleukin-2 (IL-2) depot preparations (n = 30) or albumin (placebo) depot preparations (n = 30) implanted directly into one tumor site. IL-2 depots released IL-2 reliably for more than 24 days. The rat serum was tested during treatment for human IL-2, possibly absorbed from depots, and for rat interferon γ. IL-2 treatment reduced tumor growth significantly (P < 0.001) compared with albumin-treated sites or untreated contralateral sites. No toxicity was observed during treatment. Neither human IL-2 nor rat interferon γ was detected in the serum, which indicates an exclusively local IL-2 effect. IL-2 depot preparations reduce tumor growth in Dunning adenocarcinoma of the prostate significantly without toxicity.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 17 June 1997 / Accepted: 1 August 1997
Rights and permissions
About this article
Cite this article
Hautmann, S., Huland, E. & Huland, H. Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats. J Cancer Res Clin Oncol 123, 614–618 (1997). https://doi.org/10.1007/s004320050114
Issue Date:
DOI: https://doi.org/10.1007/s004320050114